Related Experiment Video
Updated: Jun 15, 2026
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Basic principles of platelet biology and clinical implications.
Dominick J Angiolillo1, Masafumi Ueno, Shinya Goto
1Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL 32209, USA. dominick.angiolillo@jax.ufl.edu
Summary
Platelet activation is key in hemostasis and thrombosis. Current antiplatelet drugs reduce risk, but novel agents targeting pathways like P2Y12 and thrombin offer improved inhibition for atherothrombosis prevention.
Area of Science:
- Cardiovascular Biology
- Hematology
- Pharmacology
Background:
- Platelet activation and aggregation are crucial for hemostasis but also implicated in atherothrombotic events.
- Excessive platelet activity contributes to occlusive thrombi formation, leading to acute ischemic events.
- Existing antiplatelet therapies targeting thromboxane A2 (TXA2) and adenosine diphosphate (ADP) P2Y12 receptor pathways have limitations, leaving residual risk.
Purpose of the Study:
- To review the fundamental principles of platelet biology.
- To discuss currently available antiplatelet agents and their mechanisms.
- To explore novel antiplatelet agents under clinical development for enhanced efficacy.
Main Methods:
- Review of platelet activation pathways (ADP, TXA2, serotonin, collagen, thrombin).
- Analysis of established antiplatelet agents (e.g., aspirin, clopidogrel).
- Examination of emerging antiplatelet therapies targeting TXA2, P2Y12, and protease-activated receptor-1 (PAR-1).
Main Results:
- Current antiplatelet agents significantly reduce atherothrombotic risk but do not eliminate it.
- Residual platelet reactivity persists in some patients despite treatment.
- Novel agents aim for more potent platelet inhibition through various mechanisms.
Conclusions:
- Understanding platelet biology is essential for developing effective antiplatelet strategies.
- Newer agents targeting potent P2Y12 antagonism and PAR-1 inhibition show promise.
- Further research into novel antiplatelet therapies is needed to address residual risk in atherothrombosis.
Related Concept Videos
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.